Condition: Extensive-stage Small Cell Lung Cancer (ES-SCLC) · Thoracic Neoplasms · Lung Neoplasms · Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
This description comes directly from the study's public registry record.
jiale Wang · +86 21 65115006 · wangjiale200008@163.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. extensive stage small cell lung cancer 2. Progression after receiving at least one chemotherapy drug treatment in the past; 3. ECOG score 0-1 4. c-Myc-driven 5. Expected survival period ≥3 months 6. Age: 18-75 years old; 7. The informed consent form complies with the ICH-GCP principles. Exclusion Criteria: 1. No measurable lesions 2. Other severe and persistent diseases or organ system dysfunction; 3. Women planning pregnancy or men planning family planning; 4. Women who are pregnant or breastfeeding; 5. Those who cannot follow the research protocol provided by the investigator.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Shanghai Pulmonary Hospital, Shanghai, China | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.